Latest Articles
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone - Medpage Today
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone Medpage Today
Published: June 5, 2024, 7 a.m.
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates - PR Newswire
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire
Published: June 1, 2024, 7 a.m.
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer - OncLive
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer OncLive
Published: April 24, 2024, 7 a.m.
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer - Oncology Learning Network
Rucaparib Maintenance Therapy in Recurrent/Metastatic Endometrial Cancer Oncology Learning Network
Published: March 21, 2024, 7 a.m.
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer - Medpage Today
Rucaparib Maintenance Boosts PFS in Metastatic, Recurrent Endometrial Cancer Medpage Today
Published: March 19, 2024, 7 a.m.
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer - Oncology News Central
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer Oncology News Central
Published: March 17, 2024, 7 a.m.
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer - EurekAlert
RUBY Part 2 trial results: Potentially practice changing results in advanced/recurrent endometrial cancer EurekAlert
Published: March 16, 2024, 7 a.m.
Link copied to clipboard!